PET to assess early metabolic response and to guide treatment of adenocarcinoma of the oesophagogastric junction: the MUNICON phase II trial

Florian Lordick(Leipzig University), J. R. Siewert(Technical University of Munich), Ken Herrmann(Essen University Hospital), Tibor Schuster(Technical University of Munich), Katja Ott(Technical University of Munich), Hinrich Wieder(Klinikum rechts der Isar), Christian Peschel(Technical University of Munich), H. J. Stein(LMU Klinikum), Wolfgang Weber(Nuklearmedizinische Klinik des Klinikums rechts der Isar), Rainer Bredenkamp(Klinikum rechts der Isar), U. Fink(Technical University of Munich), Karen Becker(Technical University of Munich), Heinz Höfler(Klinikum rechts der Isar), Markus Schwaiger(Technical University of Munich), Bernd‐Joachim Krause(Technical University of Munich), Sylvie Lorenzen(Technical University of Munich)
The Lancet Oncology
August 11, 2007
10.1016/s1470-2045(07)70244-9
Cited by 808

Related Papers

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
|The Lancet|2010|7.3k
Gastric cancer
|The Lancet|2020|4.8k
Gastric cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
|Annals of Oncology|2022|1.4k
Randomized Phase III KEYNOTE-181 Study of Pembrolizumab Versus Chemotherapy in Advanced Esophageal Cancer
|Journal of Clinical Oncology|2020|1.2k
Oesophageal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
|Annals of Oncology|2016|1.1k